BioCentury
ARTICLE | Product Development

March 19 COVID-19 Product Development Roundup: Actemra trial begins; plus CytoDyn's leronlimab, a post-exposure prophylaxis trial, and Abbott's EUA

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

March 19, 2020 8:32 PM UTC
Updated on Mar 25, 2020 at 9:49 PM UTC

The start of a placebo-controlled Phase III trial of Genentech's Actemra to treat hospitalized patients with COVID-19 was one of several signs of progress Thursday among programs to treat or diagnose the disease.

Along with competing IL-6 inhibitor Kevzara sarilumab from Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Actemra tocilizumab is being studied to evaluate its effects on later-stage patients with severe disease...